June 3, 2018 07:30 AM EDT

Merck's Keytruda builds a commanding lead in frontline lung cancer with data from two more landmark trials

CHICAGO — Merck came to ASCO as the dominant industry player in frontline lung cancer. It’s going to leave ASCO with that rep intact — at the …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Mer­ck­'s Keytru­da builds a com­mand­ing lead in front­line lung can­cer with da­ta from two more land­mark tri­als